Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab

Torre, 2012, Global cancer statistics, CA. Cancer J. Clin., 65, 87

Moro-Sibilot, 2015, Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study, Lung Cancer, 88, 215, 10.1016/j.lungcan.2015.02.011

Shepherd, 2000, Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy, J. Clin. Oncol., 18, 2095, 10.1200/JCO.2000.18.10.2095

Hanna, 2004, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy, J. Clin. Oncol., 22, 1589, 10.1200/JCO.2004.08.163

Shepherd, 2005, Erlotinib in previously treated non-small-cell lung cancer, N. Engl. J. Med., 353, 123, 10.1056/NEJMoa050753

Reck, 2014, Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial, Lancet. Oncol., 15, 143, 10.1016/S1470-2045(13)70586-2

Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N. Engl. J. Med., 373, 123, 10.1056/NEJMoa1504627

Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N. Engl. J. Med., 373, 1627, 10.1056/NEJMoa1507643

Herbst, 2015, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet (London, England), 78, 700

Rizvi, 2015, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348

Diakos, 2014, Cancer-related inflammation and treatment effectiveness, Lancet Oncol., 15, e493, 10.1016/S1470-2045(14)70263-3

Yuan, 2015, Opposite effects of M1 and M2 macrophage subtypes on lung cancer progression, Sci. Rep., 5, 14273, 10.1038/srep14273

Tao, 2012, Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells, Lung Cancer, 75, 95, 10.1016/j.lungcan.2011.06.002

Stone, 2012, Paraneoplastic thrombocytosis in ovarian cancer, N. Engl. J. Med., 366, 610, 10.1056/NEJMoa1110352

Guthrie, 2013, The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer, Crit. Rev. Oncol. Hematol., 88, 218, 10.1016/j.critrevonc.2013.03.010

Templeton, 2014, Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis, J. Natl. Cancer Inst., 106, 10.1093/jnci/dju124

Templeton, 2014, Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio, Cancer, 10.1002/cncr.28890

Templeton, 2014, Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis, Cancer Epidemiol. Biomarkers Prev., 23, 1204, 10.1158/1055-9965.EPI-14-0146

Proctor, 2012, A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer, Br. J. Cancer, 107, 695, 10.1038/bjc.2012.292

Zaragoza, 2016, A high neutrophil-to-lymphocyte ratio as a potential marker of mortality in patients with Merkel cell carcinoma: a retrospective study, J. Am. Acad. Dermatol., 10.1016/j.jaad.2016.05.045

Zhang, 2015, Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer, Am. J. Surg., 210, 526, 10.1016/j.amjsurg.2015.03.022

Zhang, 2015, Prognostic significance of combination of preoperative platelet count and Neutrophil-Lymphocyte ratio (COP-NLR) in patients with non-small cell lung cancer: based on a large cohort study, PLoS One., 10, e0126496, 10.1371/journal.pone.0126496

Delyon, 2013, Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival, Ann. Oncol., 24, 1697, 10.1093/annonc/mdt027

Ku, 2010, Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival, Cancer, 116, 1767, 10.1002/cncr.24951

Kelderman, 2014, Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma, Cancer Immunol. Immunother., 63, 449

Ferrucci, 2016, Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab, Ann. Oncol., 27, 732, 10.1093/annonc/mdw016

Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur. J. Cancer., 45, 228, 10.1016/j.ejca.2008.10.026

Borghaei, 2016, Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses, J. Thorac. Oncol., 11, S237, 10.1016/j.jtho.2016.08.106

Yang, 2016, The efficacy and potential predictive factors of PD-blockades in epithelial carcinoma patients: a systematic review and meta analysis, Oncotarget, 7, 74350, 10.18632/oncotarget.11291

Albain, 1991, Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience, J. Clin. Oncol., 9, 1618, 10.1200/JCO.1991.9.9.1618

Emens, 2015, The interplay of immunotherapy and chemotherapy: harnessing potential synergies, Cancer Immunol. Res., 3, 436, 10.1158/2326-6066.CIR-15-0064

Shaverdian, 2017, Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial, Lancet. Oncol., 18, 895, 10.1016/S1470-2045(17)30380-7

Gu, 2015, Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis, Sci. Rep., 5, 12493, 10.1038/srep12493

Liu, 2016, Neutrophil-lymphocyte ratio as a prognostic marker for chemotherapy in advanced lung cancer, Int. J. Biol. Markers., 31, e395, 10.5301/jbm.5000222

Sim, 2016, Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors, Thorac. Cancer., 7, 161, 10.1111/1759-7714.12304

Bagley, 2017, Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer, Lung Cancer, 106, 1, 10.1016/j.lungcan.2017.01.013